Literature DB >> 30229465

A negative multiparametric magnetic resonance imaging finding does not guarantee the absence of significant cancer among biopsy-proven prostate cancer patients: a real-life clinical experience.

Jung Jun Kim1, Seok-Soo Byun1,2, Sang Eun Lee1, Hak Jong Lee3, Gheeyoung Choe4, Sung Kyu Hong5,6.   

Abstract

PURPOSE: We analyzed the data of consecutive patients who had preoperative multiparametric magnetic resonance imaging (mpMRI) and underwent radical prostatectomy (RP) to evaluate the actual performance of mpMRI among biopsy-proven prostate cancer (PCa) patients in predicting favorable pathology in the real-life clinical setting.
METHODS: Among a total 730 biopsy-proven PCa patients underwent RP, the preoperative mpMRIs of 534 patients were positive, demonstrating one or more PI-RADs V2 grade ≥ 2 lesion(s). Other 196 mpMRIs were classified as negative, without any suspicious lesion. Pathology was classified to be unfavorable when showing Gleason score (GS) 4/5 or pT3/N1 features. Significant cancer was defined as non-organ-confined, GS 4/5, or cancer volume of ≥ 0.5 mL.
RESULTS: Among a total 196 negative preoperative mpMRI patients, final RP pathology showed that 20 (10.2%) had pT3 disease and 2 (1.0%) had pN1 disease. Regarding the pathologic Gleason score, 117 (59.7%) had GS 3 + 4 and 44 (22.4%) had GS ≥ 4 + 3. The rate of a favorable PCa and an insignificant cancer was as low as 14.3% and 10.2%. Even among only the 101 D'Amico low-risk patients with negative MRI, the rates of a favorable pathology and an insignificant cancer were only 18.2% and 12.7%. The sensitivity, specificity, positive, and negative predictive value of mpMRI to predict a significant cancer were 74.3%, 45.5%, 95.5%, and 10.2%, respectively.
CONCLUSIONS: In the real-life clinical setting, mpMRI demonstrated limited performance in the prediction of favorable and insignificant prostate cancer as a negative mpMRI could not guarantee the absence of unfavorable pathology among PCa patients.

Entities:  

Keywords:  Favorable pathology; Insignificant cancer; Multiparametric magnetic resonance imaging

Mesh:

Year:  2018        PMID: 30229465     DOI: 10.1007/s11255-018-1986-7

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  3 in total

1.  The diagnostic accuracy of multiparametric MRI for detection and localization of prostate cancer depends on the affected region.

Authors:  Martina Martins; Stefano Regusci; Stephane Rohner; Ildiko Szalay-Quinodoz; Georges-Antoine De Boccard; Louise Strom; Gerjon Hannink; Sonia Ramos-Pascual; Charles Henry Rochat
Journal:  BJUI Compass       Date:  2020-11-28

Review 2.  Role of Multiparametric Magnetic Resonance Imaging in Predicting Pathologic Outcomes in Prostate Cancer.

Authors:  Niklas Harland; Arnulf Stenzl; Tilman Todenhöfer
Journal:  World J Mens Health       Date:  2020-06-24       Impact factor: 5.400

3.  Identifying Risk Factors for MRI-Invisible Prostate Cancer in Patients Undergoing Transperineal Saturation Biopsy.

Authors:  Alberto Artiles Medina; Rafael Rodríguez-Patrón Rodríguez; Mercedes Ruiz Hernández; Marina Mata Alcaraz; Silvia García Barreras; Guillermo Fernández Conejo; Agustín Fraile Poblador; Enrique Sanz Mayayo; Francisco Javier Burgos Revilla
Journal:  Res Rep Urol       Date:  2021-09-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.